NMN Supplementation Shows Potential in Improving Vascular Health and NAD+ Metabolism
Introduction: Nicotinamide mononucleotide (NMN) has shown promising effects in animal studies, protecting against age-related diseases by preventing the reduction of NAD+ levels. However, there is limited clinical data on the effects of NMN supplementation in humans. This study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters.
Study Design and Results
The study involved 36 healthy middle-aged participants who were randomly assigned to either the NMN intake or placebo group. Participants received either 125 mg NMN or placebo twice a day. After the intervention, it was observed that NMN supplementation significantly increased nicotinamide levels in the serum. Although arterial stiffness (as indicated by pulse wave velocity) tended to decrease in the NMN group, the difference was not statistically significant compared to the placebo group. Importantly, long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events.
Discussion
NMN supplementation effectively elevated NAD+ metabolism in middle-aged adults without adverse effects. Additionally, NMN exhibited potential in alleviating arterial stiffness, especially in individuals with higher BMI or blood glucose levels. The ameliorating effect of NMN on diastolic blood pressure may help reduce cardiovascular disease risk. Further clinical trials are necessary to establish the benefits of NMN in reducing arterial stiffness and cardiovascular risk factors.
Methodology
The study followed a randomized, double-blind, placebo-controlled design in which 36 healthy subjects aged 40-59 years were enrolled. They were randomly assigned to either the NMN supplementation or placebo group. NMN (125 mg/capsule) or placebo capsules were taken twice daily for 12 weeks. Laboratory tests, safety evaluations, and various measurements were conducted before and after the intervention. Statistical analyses were performed to assess the efficacy and safety of NMN supplementation.
Conclusion
This study provides initial evidence that NMN supplementation can safely increase NAD+ metabolism in middle-aged individuals. While there were positive trends in reducing arterial stiffness, further research is needed to confirm these effects and establish NMN's potential in reducing cardiovascular disease risk factors.
Note: For detailed information and data tables, please refer to Supplementary Tables S1 and S2 provided by the study.
Title of paper: Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial
Author(s): Katayoshi T, Uehata S, Nakashima N, Nakajo T, Kitajima N, Kageyama M, Tsuji-Naito K.
Year published: 2023
Published in: Sci Rep
Original article can be found here.
